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Structure-based drug designKeap1 protein acts as a cellular sensor for oxidative stresses and regulates the transcription level of
antioxidant genes through the ubiquitination of a corresponding transcription factor, Nrf2. A small
molecule capable of binding to the Nrf2 interaction site of Keap1 could be a useful medicine. Here,
we report two crystal structures, referred to as the soaking and the cocrystallization forms, of the
Kelch domain of Keap1 with a small molecule, Ligand1. In these two forms, the Ligand1 molecule
occupied the binding site of Keap1 so as to mimic the ETGE motif of Nrf2, although the mode of
binding differed in the two forms. Because the Ligand1 molecule mediated the crystal packing in
both the forms, the inﬂuence of crystal packing on the ligand binding was examined using a molec-
ular dynamics (MD) simulation in aqueous conditions. In the MD structures from the soaking form,
the ligand remained bound to Keap1 for over 20 ns, whereas the ligand tended to dissociate in the
cocrystallization form. The MD structures could be classiﬁed into a few clusters that were related to
but distinct from the crystal structures, indicating that the binding modes observed in crystals
might be atypical of those in solution. However, the dominant ligand recognition residues in the
crystal structures were commonly used in the MD structures to anchor the ligand. Therefore, the
present structural information together with the MD simulation will be a useful basis for pharma-
ceutical drug development.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Living organisms have speciﬁc defense systems against various
environmental stresses. Of all these stresses, the oxidative stress
have been a focus of constant attention in medicine because it is
related to many pathologies including cancer [1,2], cardiovascular
disease [3,4], diabetes [5,6], neurodegenerative disease [7,8],
chronic arthritis [9,10] and aging [11,12]. Understanding of the
antioxidant response system is important to develop medical
treatments for these pathologies [13]. The antioxidant response
is accomplished by the sensing of oxidants and the subsequent
activation of antioxidant genes [14]. The sensing of oxidants suchas reactive oxygen species and electrophilic xenobiotics is carried
out by the Kelch-like ECH-associated protein 1 (Keap1) [15]. On
the other hand, the nuclear factor erythroid 2-related factor 2
(Nrf2) protein [16] is responsible for the transcriptional regulation
of about 200 antioxidant proteins including many enzymes/trans-
porters for drug metabolism and Nrf2 itself [17]. Keap1 is suscep-
tible to a posttranslational modiﬁcation by oxidants at certain
reactive cysteine residues, allowing Keap1 to sense them [18,19].
Keap1 and other proteins assemble to make the Cullin 3-based
E3 ubiquitin ligase complex that binds and ubiquitinates Nrf2.
After the ubiquitination, Nrf2 is rapidly degraded by proteasome
to keep the lower level of intracellular Nrf2, and therefore the tran-
scription of antioxidant genes is suppressed in the quiescent cells
[19,20]. The oxidative-stress-induced modiﬁcation of Keap1 at
speciﬁc cysteine residues inhibits the Nrf2 ubiquitination, thereby
elevating the intracellular Nrf2 level [19]. As a result, the intact
Nrf2 activates the transcription of antioxidant genes through mak-
ing a complex with the small Maf protein and subsequent binding
Fig. 1. Chemical structure of ligands.
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ment located in the promoter regions of target genes [16].
The Keap1 molecule mainly consists of the N-terminal domain,
the C-terminal Kelch domain and the intervening region located
in-between the two domains. A single particle analysis of electron
microscopy conﬁrmed that Keap1 in solution state forms a homod-
imer assembled at two cognate N-terminal domains [21]. The
N-terminal domain also mediates interactions with other compo-
nents of the Cullin 3-based E3 ubiquitin ligase complex [22], and
contains a cysteine residue Cys151 that senses the oxidative stress
[19]. The other sensing cysteine residues Cys273 and Cys288 pre-
sent in the intervening region [18]. The Kelch domain is responsi-
ble for the interaction with Nrf2. As the binding site to Keap1, the
ETGE motif located in the N-terminal region of Nrf2 was found ﬁrst
[23]. The DLG motif in the N-terminal region was identiﬁed later,
as the second binding site required for the ubiquitination/degrada-
tion of Nrf2 [24]. Biophysical analyses using nuclear magnetic res-
onance and isothermal titration calorimetry revealed that the DLG
and ETGE motifs interact independently with the Kelch domain by
different dissociation constants of 0.5 lM and 8 nM, respectively
[25]. Based on analyses in molecular biology, McMahon et al. pro-
posed a two-site interaction model so-called ‘‘tethering’’ mecha-
nism in which two Kelch domains of the Keap1 dimer recognize
a single molecule of Nrf2 to facilitate the Cullin-mediated ubiqui-
tination of Nrf2 [26].
These studies imply that a small molecule capable of binding to
the Nrf2 interaction site on the Keap1 Kelch domain could be a use-
ful medicine to activate the cellular defense to the oxidative stress
through inhibiting the ubiquitination of Nrf2. Although several
candidates for such compounds were reported, no one was applied
in practical use [27–29]. Precise structural information, for
instance, from the X-ray crystallography at high resolution, is
indispensable for the structure-based drug design. To date, several
crystal structures were reported: the Kelch domain [30], the Kelch
domain in complex with the Nrf2 peptide containing the ETGE
motif [31,32] or the DLG motif [33,34]. However, structural infor-
mation of Keap1 complexes with small molecule ligands is still
limited; only two complex structures have been reported recently
[35,36]. Structural comparison between multiple crystal structures
of Keap1 complexes with different small molecule ligands would
be useful for the more effective design of Keap1 inhibitors [28].
Here we determined a crystal structure of the Kelch domain of
human Keap1 in complex with a small ligand referred to as
Ligand1 that has a novel chemical scaffold. Interestingly, two dif-
ferent binding modes were observed in the Keap1–Ligand1 com-
plex crystals.2. Results and discussion
2.1. Screening and characterization of Ligand1
To search for the candidate compounds, an in silico screening
was performed on the crystal structure of the Kelch domain of
human Keap1 in complex with the ETGE peptide of Nrf2 (PDB entry
2ﬂu) [32]. The in-house and commercially available compounds
were docked against the Nrf2 peptide binding site. Based on the
docking score and the predicted afﬁnity against Keap1, 65 com-
pounds were selected. Then, the binding ability of these com-
pounds was evaluated using a surface plasmon resonance-based
solution assay at 50 lM of the compound concentration. We found
27 active compounds including the LigandX (Fig. 1).
Based on the structural comparison between the docking pose
of LigandX and the ETGE peptide of Nrf2 in 2ﬂu, we designed
and synthesized the Ligand1 in which the phenol moiety of
LigandX was modiﬁed by the oxyacetic acid group that intendedto mimic the sidechain of the ﬁrst (N-terminal) glutamic acid resi-
due in the ETGE peptide (see Section 4 for the synthesis of
Ligand1). The association constant of Ligand1 to the human
Keap1 Kelch domain was estimated as the third to the fourth
power of ten from the equilibrium afﬁnity analysis of a surface
plasmon resonance-based solution experiment (Fig. 2).
Unfortunately, the limited solubility of Ligand1 (less than 1 mM)
hampered further analyses on binding properties including the
precise association constant, the number of binding sites, and the
cooperativity. The Keap1–Ligand1 interaction was also conﬁrmed
by another assay using AlphaScreen (PerkinElmer Inc.), a
bead-based, ampliﬁed luminescent proximity homogeneous assay,
which revealed the competitive effect of Ligand1 on the interaction
between the Nrf2 peptide and the Kelch domain of Keap1
(Supplemental Fig. S1).
2.2. Quality of crystal structures
Two crystal structures of the human Keap1 Kelch domain in
complex with Ligand1, the soaking form and the cocrystallization
form, were determined at 2.1 Å resolution (Table 1). In these two
forms, the asymmetric unit contained a Kelch domain and a
Ligand1 molecule. The ﬁnal models of the Kelch domain covered
the amino-acid residues 322–609 with well-deﬁned electron den-
sities, while the N-terminal 21 residues (20 His-tag residues and
Ala321) were not included due to a structural disorder, as observed
in the crystal structure of the same Kelch domain reported (PDB
entry 1u6d) [30]. The temperature factor (B) values calculated from
ﬁnal models (average) were comparable to the Wilson B values
from corresponding diffraction data. The soaking form crystal
was isomorphous to 1u6d with the space group P6522, whereas
the cocrystallization form revealed a different crystal packing with
the other space group P212121. The stereochemistry analysis
revealed no residue in generously allowed or disallowed regions
of the Ramachandran plot, except for Arg336 and His516 in the
generously allowed region. These two residues were found in
well-deﬁned electron densities without steric clashes. All atoms
comprising Ligand1 were identiﬁed in electron density maps with
reasonable individual B values comparable to those of neighboring
protein atoms, indicating high occupancy of the ligand (Table 1).
Thus we ﬁxed the occupancies of all atoms comprising Ligand1
to 1.0 and did not reﬁne them. In addition, annealed 2FoFc omit
maps for Ligand1 in both the forms provided clear electron densi-
ties comparable to those of corresponding ﬁnal 2FoFc maps
(Supplemental Fig. S2), conﬁrming the existence of ligands bound.
2.3. Recognition of Ligand1
The overall structural architecture of the human Keap1 Kelch
domain in our structures is the same as that in the PDB entry
1u6d that represents the b-propeller structure composed of a six-
fold repeat of all b domain called ‘‘blade’’ [30]. The Rmsd values
Table 1
Statistics from crystallographic analysis.
Crystal form Soaking Cocrystallization
Data collection
Space group P6522 P212121
Unit-cell parameters (Å) a = 85.368, c = 145.903 a = 51.328, b = 66.514, c = 77.765
Resolution range (Å) 40–2.10 (2.18–2.10) 40–2.10 (2.18–2.10)
No. of unique reﬂections 19,075 (1859) 16,129 (1568)
Redundancy 32.1 (32.3) 6.7 (6.8)
Completeness (%) 100.0 (100.0) 100.0 (100.0)
<I/r(I)> 40.3 (12.8) 31.9 (19.4)
a Rmerge (%) 9.5 (37.1) 5.3 (8.4)
Wilson B value (Å2) 20.5 17.4
Reﬁnement
Resolution range (Å) 40–2.10 (2.23–2.10) 40–2.10 (2.23–2.10)
No. of reﬂections 18,954 (3061) 16,089 (2631)
b Rcryst/Rfree (%) 20.1 (23.6)/21.1 (24.7) 19.6 (19.6)/22.5 (23.2)
Protein <B>(Å2)/No. of atoms 20.5/2217 14.1/2217
Ligand <B>(Å2)/No. of atoms 37.6/26 15.8/26
Water <B>(Å2)/No. of atoms 35.6/247 34.7/407
Total <B>(Å2)/No. of atoms 22.2/2490 17.3/2650
Rmsd bond lengths (Å) 0.012 0.011
Rmsd bond angles () 1.70 1.60
Ramachandran plot (%)
Most favoured 88.7 89.1
Additional allowed 10.5 10.5
Generously allowed 0.8 0.4
Disallowed 0.0 0.0
PDB code 3vnh 3vng
a Rmerge =
P
hkl
P
i|Ii(hkl)  <I(hkl)>|/
P
hkl
P
i Ii(hkl), where Ii(hkl) is the ith observation of reﬂection hkl and < I(hkl)> is the
weighted average intensity for all observations i of reﬂection hkl.
b Rcryst =
P
hkl||Fobs|  |Fcalc||/
P
hkl|Fobs|, where |Fobs| and |Fcalc| are the observed and calculated structure-factor amplitudes,
respectively. Rfree was calculated with 5% of the reﬂections chosen at random and omitted from reﬁnement. Values in
parentheses are for the outermost shell.
Fig. 2. Surface plasmon resonance-based solution experiment to evaluate the Keap1–Ligand1 interaction. The sensorgram from the immobilized GST fusion of Keap1 Kelch
domain on the sensor chip with four different concentrations of Ligand1 after the bulk solvent correction and reference correction using GST is shown. The color codes used
were: red for 12.5 lM, magenta for 25 lM, green for 50 lM and sky blue for 100 lM. The starting and the stopping points of the ligand addition are indicated by red and blue
arrows, respectively.
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1u6d and our structures are 0.241 Å for the soaking form and
0.431 Å for the cocrystallization form. The latter value is similar
to that from the Ca superposition between the soaking and the
cocrystallization forms: 0.449 Å. Reﬂecting the crystal packing dif-
ference, the N-terminal three residues adopt totally different
main-chain conformations in the cocrystallization form when
compared to other forms, thereby excluding these residues in the
superposition. Elsewhere, the cocrystallization form is similar to
the others in terms of the main-chain structure. On the other hand,1u6d and the soaking form confer essentially the same main-chain
structure including the N-terminal region.
When the soaking and the cocrystallization forms are com-
pared, the Ligand1 molecule is found on the same side of the
6-bladed b-propeller that is opposite to the N- and C-termini.
However, the precise locations of two binding sites are distinct
(Fig. 3B and C). In the soaking form, the Ligand1 molecule approx-
imately locates on the central hole of Keap1. On the other hand, in
the cocrystallization form, the binding site of Ligand1 relocates by
about 10 Å toward the ﬁrst blade. The Ligand1 molecule is
Fig. 3. Structure of Keap1 in complex with Ligand1. (A) Schematic representation of Keap1–Ligand1 interactions. The notation of atoms is the same as that used in the PDB
entries 3vng and 3vnh. The atom names beginning C, N and O denote carbon, nitrogen and oxygen atoms, respectively. The atoms recognized by Keap1 in the soaking form, in
the cocrystallization form and in both the forms are colored red, blue and purple, respectively. Unrecognized atoms are colored gray. (B) Stereo representation of the soaking
form structure. The Keap1 domain and the Ligand1 molecule are depicted as a ribbon drawing and a stick model, respectively. The blades of b-propeller are labeled. The ﬁnal
2Fo  Fc electron densities at 2.1 Å resolution contoured at 1r are shown around the Ligand1 model. (C) Cocrystallization form structure shown in the same manner as (B).
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in the cocrystallization form (Table 2). These residues are
well-conserved in the Keap1 members from various organisms.
Interestingly, some of these residues are overlapped, indicating
an apparent multiple recognition mode to the same ligand
(Fig. 3A). The residues used in both the forms are Tyr334, Ser363,
Arg380, Asn382 and Asn414. On the other hand, the
form-speciﬁc recognition residues are Arg415, Arg483, Ser508,
Ala556 and Gly603 for the soaking form, whereas Arg336 and
Ser602 for the cocrystallization form. Interaction types used are:
1 hydrogen bond, 1 water-mediated hydrogen bond, 3 electrostatic
interactions and 19 nonpolar interactions for the soaking form; 5
hydrogen bonds, 3 water-mediated hydrogen bonds and 11nonpolar interactions for the cocrystallization form. Thus, in terms
of the interaction type, nonpolar interactions and hydrogen bonds
dominate in the soaking and the cocrystallization forms,
respectively.
From a detailed comparison between 1u6d and the soaking
form, a ligand-induced rearrangement of side-chain atoms is
observed at several ligand recognition residues: Arg380, Asn382,
Arg415, Arg483 and Ser508. On the other hand, from that between
1u6d and the cocrystallization form, another ligand-induced rear-
rangement is observed at a few ligand recognition residues: the
side-chains of Arg336 and Arg380, and the main-/side-chain of
Asn382. In addition, probably reﬂecting the crystal packing, several
peripheral loops adopt slightly different main-/side-chain
Table 2
Recognition of Ligand1 by Keap1.
Soaking Cocrystallization Type Distance (Å)
Keap1 Water Ligand1 Keap1 Water Ligand1
Tyr334 Ce2 CAZ NP 3.19
Cf CAY NP 3.37
Og CAY NP 3.30
Og CAI NP 3.14
Og CAD NP 3.33
Tyr334 Cc CAL NP 3.34
Og NAO HB 3.07
Arg336 Ne CAD NP 3.25
Ne CAI NP 3.34
Ne CAF NP 3.39
O W413 HB 2.66
W413 NAP HB 2.50
Ser363 Oc NAM NP 3.39
Oc OAB NP 3.40
Ser363 Cb OAA NP 3.10
Oc OAA HB 2.57
Oc CAT NP 3.21
Oc OAC NP 3.31
Arg380 Ng2 NAN NP 3.07
Arg380 Ne OAC HB 2.88
Cf OAC NP 3.30
Ng2 OAC HB 2.88
Ng2 OAQ NP 3.22
Asn382 Cc OAR NP 3.02
Od1 OAR NP 2.91
Od1 CAF NP 3.03
Asn382 Cb OAC NP 3.21
Nd2 OAC HB 3.05
Nd2 OAQ NP 3.31
Asn414 Od1 W445 HB 2.67
W445 OAB HB 2.58
Asn414 Od1 W433 HB 2.81
W433 OAA HB 3.07
Arg415 Ng1 OAA ES 3.51
Ng1 OAQ NP 3.05
Ng2 NAP NP 3.08
Ng2 CAX NP 3.20
Ng2 CAU NP 3.26
Arg483 Ne OAC ES 3.47
Ng2 OAC ES 3.44
Ser508 Cb OAC NP 3.14
Oc OAC HB 2.74
Oc CAT NP 3.12
Ala556 Cb CAV NP 3.39
Ser602 Oc W424 HB 2.79
W424 OAA HB 2.90
Gly603 Ca CAK NP 3.11
Interactions are classiﬁed in three types: HB as a hydrogen bond with a distance not greater than 3.4 Å (angle considered); NP as a nonpolar interaction with a distance not
greater than 3.4 Å; ES as an electrostatic interaction with a distance not greater than 4.0 Å.
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of the second blade (residues 380–389) in which two ligand recog-
nition residues Arg380 and Asn382 exist, shows a limited confor-
mational change in the main-/side-chain structure, probably
reﬂecting both the ligand binding and the crystal packing differ-
ence. Therefore, this b-hairpin in the second blade may be impor-
tant for the ligand recognition. Among six b-hairpin protrusions of
Keap1, only that of the ﬁrst blade (residues 334–338) adopts rela-
tively rare class 1 conformation [37] where two ligand recognition
residues Tyr334 and Arg336 exist; other ﬁve b-hairpins adopt the
class 2 conformation. Interestingly, the six b-hairpins of Keap1
are accompanied with similar uncommon b-bulges including the
invariant glycine doublet, which cannot be classiﬁed by the current
criteria [38] of b-bulge. In the soaking form, a ligand recognition
residue Arg483 locates on the b-hairpin in the fourth blade(residues 478–483). Since they harbor the ligand binding residues,
the b-hairpins in the ﬁrst and the fourth blades may also be impor-
tant for the ligand recognition, although they do not show large
conformational differences in the main-chain structure upon bind-
ing ligand.
2.4. Structural comparison between Ligand1 and Nrf2
To understand the binding ability of Ligand1 to Keap1, present
two Keap1–Ligand1 complexes were compared with other
reported Keap1 complex structures that contain peptides from
the physiological ligand, Nrf2. The clearest result was obtained
from the Keap1 complex structure with the ETGE peptide of
Nrf2: 1x2r [31], 2ﬂu [32] and 3zgc [39]. When the soaking and
the cocrystallization forms are superimposed onto 1x2r at
Fig. 4. Structural comparisons. The Keap1 domain and the Ligand1 molecule are
depicted as a ribbon drawing and a stick model, respectively. Representative
residues for the ligand recognition are shown as stick models and labeled. (A)
Ligand1 in the soaking form compared with the ETGE peptide. The ETGE peptide
from the PDB entry 1x2r [31] is superposed and shown in a magenta wire model
with side-chain stick models for the ﬁrst glutamate at bottom, the threonine at
middle and the second glutamate at top. (B) Ligand1 in the cocrystallization form
compared with the ETGE peptide. The ETGE peptide superposed is shown in the
same manner as (A). (C) Superposition between the soaking and the cocrystalliza-
tion forms.
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with the ﬁrst and the second glutamate of the ETGE motif,
respectively (Fig. 4A and B). The other ETGE complexes, 2ﬂu and
3zgc, provided essentially the same results. In another reportedKeap1 complex structure 3wn7 [34] containing the DLG peptide
of Nrf2, the binding mode of the DLG peptide was dissimilar to that
of Ligand1. Accordingly, the superposition of the soaking and the
cocrystallization forms clearly mimics the recognition mode of
the ETGE peptide by Keap1 (Fig. 4C). This result is consistent with
the solution experiment using AlphaScreen (PerkinElmer Inc.) in
which Ligand1 inhibits the Keap1–ETGE binding (Supplemental
Fig. S1). Other peptides from p62 [40] or prothymosin a [41] with
essentially the same binding mode as that of Keap1–ETGE may
compete with Ligand1 too. In addition, the overlapping of binding
sites for the ETGE and DLG peptides indicates that Ligand1 can
inhibit the Keap1–DLG binding partly.
This observation is similar to that in the ﬁrst report on the
Keap1 complex with small molecules by Marcotte et al. (PDB
entries 4iqk and 4in4) [35] in which the sulfone group of small
molecules located near to the acidic sidechains of the ETGE peptide
when the Keap1–peptide complex was superimposed. However,
the degree of mimicry seems to be higher in our structures where
the recognition mode for the carboxylate group of Ligand1 by the
Keap1 residues is corresponding exactly to that for the glutamate
sidechains of the ETGE peptide. In the other reported Keap1 com-
plex with small molecules by Jnoff et al. (PDB entries 4n1b, 4l7c
and 4l7d) [36], the binding mode of the small molecule is dissim-
ilar to that in our structures.
2.5. Molecular dynamics simulation
In the present structures, the Ligand1 bound to Keap1 mediates
the crystal packing (Fig. 5). The numbers of contacts with inter-
atomic distances not greater than 3.4 Å from the Ligand1 molecule
to the asymmetric and the symmetry-related molecules of Keap1
are 20 and 5 for the soaking form, whereas 16 and 7 for the cocrys-
tallization form, respectively. This indicates a substantial contribu-
tion of the crystal packing to the protein–ligand interactions in
crystals. The crystal packing is known as a possible factor to inﬂu-
ence on the structure-based drug design. For instance, the crystal
contact at the active site can hamper binding ligands when the
soaking method is used to prepare the complex crystals [42]. One
of solutions to that situation is the crystal-contact engineering to
obtain a new crystal form suitable for the ligand soaking experi-
ments where the inappropriate crystal packing is disrupted by
introducing mutations at the crystal contact [39]. However, the
inﬂuence of crystal packing on the ligand binding mode when
the packing is mediated by the ligand, is not fully investigated to
date. Thus, to examine the inﬂuence of the crystal packing, we
employed a molecular dynamics (MD) simulation in aqueous con-
dition. For instance, such MD simulation was performed to rule out
a false ligand which ejected from the binding pocket of the target
protein within 50–100 ps of simulation [43]. In another example,
an MD simulation for 20 ns was carried out to analyze the stability
of a protein–ligand complex [44].
For that reason, we performed a 20 ns MD simulation of present
Keap1–Ligand1 complexes. The time course of protein–ligand con-
tacts with interatomic distances not greater than 3.4 Å revealed
that the contact number tends to decrease (Fig. 6). In the MD struc-
tures from the soaking form, the contact numbers achieved equi-
libria with the average number of about ten. However, in those
from the cocrystallization form, several times of no contacts, indi-
cating the dissociation of ligand, were observed in the later
moments of the MD simulation. Judging from the time course of
the Rmsd from the superposition of backbone atoms between the
MD structures and the original crystal structure, the MD simula-
tion revealed a metastable state after 10 ns (Supplemental
Fig. S3). Thus, to classify the binding mode, 500 structures from
10 to 20 ns were submitted to a cluster analysis based on the
method described by Daura et al. [45]. In this analysis, the
Fig. 5. Stereo representations of crystal packing relevant to the ligand binding in the soaking form (A) and in the cocrystallization form (B). The Keap1 domain and the
Ligand1 molecule are depicted as a ribbon drawing and a stick model, respectively. The asymmetric chain and the symmetry-related chain are colored blue and red,
respectively. The ﬁnal 2Fo  Fc electron densities at 2.1 Å resolution contoured at 1r are shown around the Ligand1 model.
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center of a cluster. As a result, MD structures in a trajectory could
be classiﬁed into a few binding modes that were related to but dis-
tinct from those observed in the crystal structures (Fig. 7 and
Table 3).
In the MD structures from the soaking form, two clusters shar-
ing over 10% of 500 structures were obtained: the major cluster
sharing 204 structures with the 892nd as the center and the minor
cluster sharing 70 structures with the 774th as the center. The
crystal structure does not belong to the major or minor clusters.
In both the clusters, the guanidium groups of Arg415 and Arg483
interact with the ureido oxygen OAB and the carboxyl oxygens
OAA/OAC of Ligand1, respectively. Thus, in the MD structures from
the soaking form, Arg415 and Arg483 dominate the protein–ligand
interactions. Difference between the two clusters is that Phe478 is
used for the ligand recognition in the major cluster whereasGly509 is used in the minor cluster (Table 3). On the other hand,
in the MD structures from the cocrystallization form, three clusters
sharing over 10% of 500 structures were obtained: the major clus-
ter sharing 180 structures with the 658th as the center, the second
cluster sharing 79 structures with the 842nd as the center, the
third cluster sharing 63 structures with the 597th as the center.
Again, the crystal structure does not belong to any of these clus-
ters. In the major, the second, and the third clusters, the Ligand1
molecule locates in-between the b-hairpins of the ﬁrst and the sec-
ond blades, near the b-hairpin of the ﬁrst blade, and near the
b-hairpin of the second blade, respectively (Fig. 7B and
Supplemental Fig. S4). The second cluster showed the lowest aver-
age contact number 8.34 per structure, indicating the weakest pro-
tein–ligand interactions in these three clusters (Table 3). A
common feature of these clusters is that the guanidium group of
Arg380 interacts with the carboxyl oxygens OAA/OAC of Ligand1,
Fig. 6. Protein–ligand contact number in MD trajectories. In a 20.014 ns MD trajectory, the protein–ligand contacts with interatomic distances not greater than 3.4 Å were
counted and plotted versus time. Color codes used were red for the soaking form and blue for the cocrystallization form.
Fig. 7. Stereo representations of MD structures from the soaking form (A) and from the cocrystallization form (B). The Keap1 domain and the Ligand1 molecule are depicted
as a Ca trace and a stick model, respectively. Important residues for the ligand recognition are shown as stick models and labeled. The b-hairpins in the ﬁrst, the second and
the fourth blades are indicated as Roman numerals. In the 20.014 ns MD trajectories, only the center structure of each cluster is shown: the 892nd at 17.834 ns from the major
cluster (blue) and the 774th at 15.474 ns from the minor cluster (orange) for the soaking form; the 658th at 13.154 ns from the major cluster (blue), the 842nd at 16.834 ns
from the second cluster (orange) and the 597th at 11.934 ns from the third cluster (gray) for the cocrystallization form. These models are superimposed on the crystal
structures (green) at corresponding backbone atoms.
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Table 3
Keap1–Ligand1 contacts in MD trajectories.
Keap1 Ligand1 <Distance> (Å) Number of contacts Frequency (%)
Soaking form Number of atoms used for superposition: 53 Rmsd cutoff used for clustering: 0.9 Å
All Number of structures: 500 Total number of contacts: 4857 (9.71 contacts/structure)
<Rmsd>: 1.232 Å (Intratrajectory), 2.550 Å (3vnh-trajectory)
Arg483 Ng2 OAA 2.83 485 97.0
Arg415 Ng1 OAB 2.74 476 95.2
Arg483 Ng2 OAC 2.89 399 79.8
Ng2 CAT 3.20 381 76.2
Arg415 Cd OAB 3.13 380 76.0
Ng1 NAM 3.12 317 63.4
Arg483 Ng1 OAC 2.80 306 61.2
Ng1 OAA 2.88 263 52.6
Ser508 Cb OAA 3.14 220 44.0
Arg483 Cf OAA 3.25 190 38.0
Cf OAC 3.25 146 29.2
Ser508 Cb OAC 3.17 141 28.2
Arg483 Ng1 CAT 3.23 103 20.6
Major cluster Number of structures: 204 Total number of contacts: 1916 (9.39 contacts/structure)
<Rmsd>: 0.937 Å (Intratrajectory), 2.476 Å (3vnh-trajectory), 2.350 Å (3vnh-892nd)
Arg415 Ng1 OAB 2.75 203 99.5
Arg483 Ng2 OAA 2.81 203 99.5
Arg415 Cd OAB 3.13 178 87.3
Arg483 Ng2 OAC 2.91 152 74.5
Ng2 CAT 3.21 146 71.6
Ng1 OAC 2.79 130 63.7
Arg415 Ng1 NAM 3.12 127 62.3
Arg483 Ng1 OAA 2.90 107 52.5
Ser508 Cb OAA 3.12 101 49.5
Arg483 Cf OAA 3.24 89 43.6
Ser508 Cb OAC 3.13 66 32.4
Phe478 Cd2 OAC 3.19 56 27.5
Arg483 Cf OAC 3.26 56 27.5
Phe478 Cd2 OAA 3.20 49 24.0
Arg483 Ng1 CAT 3.24 43 21.1
Minor cluster Number of structures: 70 Total number of contacts: 734 (10.49 contacts/structure)
<Rmsd>: 0.933 Å (Intratrajectory), 2.496 Å (3vnh-trajectory), 2.453 Å (3vnh-774th)
Arg415 Ng1 OAB 2.75 70 100.0
Arg483 Ng2 OAA 2.88 67 95.7
Ng2 OAC 2.82 65 92.9
Arg415 Ng1 NAM 3.08 62 88.6
Arg483 Ng2 CAT 3.20 62 88.6
Arg415 Cd OAB 3.14 57 81.4
Arg483 Ng1 OAA 2.81 39 55.7
Ng1 OAC 2.81 36 51.4
Cf OAC 3.22 27 38.6
Ser508 Cb OAA 3.18 27 38.6
Arg483 Cf OAA 3.24 25 35.7
Ser508 Cb OAC 3.19 18 25.7
C OAA 3.15 16 22.9
C OAC 3.19 16 22.9
Gly509N OAA 3.21 14 20.0
Cocrystallization form Number of atoms used for superposition: 68 Rmsd cutoff used for clustering: 2.8 Å
All Number of structures: 500 Total number of contacts: 4222 (8.44 contacts/structure)
<Rmsd>: 4.179 Å (Intratrajectory), 4.808 Å (3vng-trajectory)
Arg380 Ng2 OAA 2.91 218 43.6
Ng2 OAC 2.91 195 39.0
Ng2 CAT 3.18 180 36.0
Tyr334 Og OAC 2.99 175 35.0
Og CAT 3.11 169 33.8
Arg336 Ng1 OAC 2.98 165 33.0
Tyr334 Og OAA 3.02 146 29.2
Arg336 Ng1 CAT 3.19 145 29.0
Ng2 OAQ 3.04 131 26.2
Ng1 OAA 3.00 126 25.2
Major cluster Number of structures: 180 Total number of contacts: 1845 (10.25 contacts/structure)
<Rmsd>: 2.543 Å (Intratrajectory), 3.995 Å (3vng-trajectory), 3.831 Å (3vng-658th)
Arg380 Ng2 OAA 2.92 119 66.1
Tyr334 Og CAT 3.10 109 60.6
Og OAC 2.99 93 51.7
Arg380 Ng2 OAC 2.88 92 51.1
Tyr334 Og OAA 3.02 81 45.0
Arg380 Ng2 CAT 3.18 80 44.4
Arg336 Ng1 OAC 3.01 61 33.9
(continued on next page)
M. Satoh et al. / FEBS Open Bio 5 (2015) 557–570 565
Table 3 (continued)
Keap1 Ligand1 <Distance> (Å) Number of contacts Frequency (%)
Ng1 CAT 3.24 57 31.7
Ng1 OAQ 3.14 57 31.7
Asn414 Nd2 OAC 2.93 53 29.4
Arg380 Ne OAC 2.96 52 28.9
Arg415 Ng2 OAA 2.85 50 27.8
Arg336 Ng1 CAL 3.22 44 24.4
Ng2 CAJ 3.25 44 24.4
Asn382 Nd2 CAH 3.22 39 21.7
Arg336 Ng1 OAA 3.02 37 20.6
Arg380 Cf OAC 3.29 37 20.6
Arg415 Ng2 CAT 3.17 37 20.6
Ng1 OAA 2.92 36 20.0
Second cluster Number of structures: 79 Total number of contacts: 659 (8.34 contacts/structure)
<Rmsd>: 2.412 Å (Intratrajectory), 5.035 Å (3vng-trajectory), 4.793 Å (3vng-842nd)
Arg336 Ng2 OAQ 2.99 54 68.4
Ng1 OAC 2.96 37 46.8
Ng2 OAC 2.85 37 46.8
Tyr334 Og OAC 2.91 28 35.4
Arg336 Ng1 CAT 3.13 28 35.4
Ng1 OAA 3.04 28 35.4
Ng2 CAT 3.22 26 32.9
Ng2 OAA 2.85 20 25.3
Ng1 OAQ 3.20 19 24.1
Cf OAC 3.26 18 22.8
O CAG 3.18 17 21.5
Arg380 Ng2 OAC 2.91 17 21.5
Gln337 Ne2 OAB 3.02 16 20.3
Third cluster Number of structures: 63 Total number of contacts: 595 (9.44 contacts/structure)
<Rmsd>: 2.390 Å (Intratrajectory), 5.489 Å (3vng-trajectory), 5.277 Å (3vng-597th)
Arg380 Ng2 OAA 2.89 50 79.4
Ng2 CAT 3.19 40 63.5
Tyr334 Og CAT 3.17 32 50.8
Og OAA 2.94 32 50.8
Og OAC 3.04 26 41.3
Arg380 Ne OAC 2.96 25 39.7
Arg415 Ng2 OAA 2.79 22 34.9
Arg380 Ng2 OAC 2.99 21 33.3
Asn414 Nd2 OAC 2.93 21 33.3
Arg380 Ng2 OAQ 3.04 20 31.7
Tyr334 Ce1 OAA 3.26 19 30.2
Arg336 Ng1 OAC 2.96 18 28.6
Ng2 OAC 3.07 14 22.2
Arg380 Ng2 CAL 3.26 14 22.2
Arg336 Ng2 OAQ 3.21 13 20.6
Arg380 Cf OAC 3.31 13 20.6
For selected structures in the latter half of 20.014 ns MD trajectory from 10.014 ns to 19.994 ns comprising 500 structures from 501st to 1000th, the protein–ligand contacts
with interatomic distances not greater than 3.4 Å were counted and listed after a descending sort by the number of contacts. Only major contacts with appearance frequency
values not less than 20% are shown. For the atomic superposition, a pair of protein–ligand atoms of which shortest interatomic distance in the 500 structures from 501st to
1000th was not greater than 3.4 Å was selected, except for the atoms with possibility of ﬂipping in the MD simulation: Cd1, Cd2, Ce1 and Ce2 of tyrosine/phenylalanine; OAA and
OAC of Ligand1.
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cluster. Notably, the structural diversity of Ligand1 is higher in
the cocrystallization form when compared to the soaking form.
From the results of the MD simulation, the binding modes
observed in crystals seem to be atypical in the solution state, indi-
cating that the MD simulation is required for the structure-based
drug design when the ligand of interest mediates the crystal pack-
ing. However, importantly, a few residues for the ligand recogni-
tion, namely, Arg380, Arg415 and Arg483, are used commonly
both in the crystal and the solution states. The binding modes
observed in the MD structures from the soaking form have certain
possibility to account for the moderate association constant of
Ligand1 in solution, because the ligand binding was retained over
20 ns in the simulation. On the other hand, the binding modes
observed in the MD structures from the cocrystallization form
may be less stable. Presumably, in the cocrystallization form, the
atypical binding mode appropriate for the crystal packing wasselected in solution when the crystal nucleation occurred. This
selection of minor and weak binding mode can occur in the case
of other protein–ligand complexes with higher afﬁnity.
3. Conclusions
To elucidate how Keap1 recognizes a small molecule ligand, we
determined the complex crystal structure of Keap1–Ligand1 in two
different forms. Because these two binding modes of Ligand1
mimic that of the physiological ligand Nrf2 peptide in different
manners, the present structural information concomitant with
the MD simulation will be a useful basis for the pharmaceutical
drug development. For instance, the fragment-based drug discov-
ery [46,47] based on the present results may contribute to design
more potent inhibitors of Keap1, although the pharmacological
efﬁcacy of Ligand 1 needs to be examined elsewhere in future. At
the same time, this work provides a lesson about the crystal
M. Satoh et al. / FEBS Open Bio 5 (2015) 557–570 567packing effect that should be considered in the interpretation of
protein–ligand complex structures. The MD simulation may be a
good tool to investigate the crystal packing effect.4. Materials and methods
4.1. Screening of compounds
The docking program FRED ver2.2 (OpenEye Scientiﬁc Software,
Inc.) and the crystal structure of the Keap1 Kelch domain in com-
plex with the Nrf2 peptide (PDB entry 2ﬂu) were used in our in sil-
ico screening and the docking pose analysis of LigandX. The
compounds in the ZINC database ver8 [48] and those in our
in-house library were used for the in silico screening. The 3D coor-
dinates of the library compounds were prepared by the program
LigPrep (Schrödinger, LLC) and the 3D conformers for the docking
were generated by the program OMEGA 2.3 (OpenEye Scientiﬁc
Software, Inc.). The MASC consensus score in FRED was used for
the compound selection.
4.2. Surface plasmon resonance-based equilibrium afﬁnity analysis
To evaluate the Keap1–Ligand1 interaction, the surface plasmon
resonance-based equilibrium afﬁnity analysis was performed
using Biacore S51 (Biacore AB/GE Healthcare). The protein sample
used was the GST fusion of the human Keap1 Kelch domain. The
Keap1 sample was immobilized on the Series S Sensor Chip CM5
(GE Healthcare) using the amine coupling kit (GE Healthcare).
The experiment was performed at 298 K in a physiological solution
[150 mM NaCl, 3.4 mM EDTA, 1% dimethylsulfoxide, 0.005%
polysorbate 20, 10 mM HEPES buffer pH 7.4]. Data analysis was
performed using the S51Evaluation program (GE Healthcare). The
number of experiments was 2 for the zero concentration of
Ligand1 and 1 for other concentrations. The resonance unit was
calculated by subtracting the response on the sample sensor spot
from that on the reference sensor spot with immobilized GST,
and by considering a bulk correction to remove the difference in
the refractive index of solvents [49]. The maximum value of reso-
nance unit was estimated as 24 in the case of single binding site,
based on the positive control experiment using the ETGE peptide
of Nrf2. The afﬁnity calculation using the steady state evaluation
of S51Evaluation failed to calculate precise afﬁnity but yielded a
range of Kd value as more than 50 lM. A manual analysis using
the double reciprocal plot based on the experimental data yielded
a rough estimation of association constant as the third to the
fourth power of ten depending upon the assumption on the bind-
ing site number.
4.3. Synthesis of Ligand1
4.3.1. Synthesis of ethyl 2-(3-cyanophenoxy)acetate
To a solution of 3-hydroxybenzonitrile (1.429 g, 12 mmol) in
acetone (120 ml), calcium carbonate (2.156 g, 15.8 mmol) and
ethyl 2-bromoacetate (2.81 g, 18.8 mmol) were added. The mixture
was stirred at room temperature for 11 h. The reaction mixture
was ﬁltered and the ﬁltrate was evaporated under reduced pres-
sure. The residue was puriﬁed by ﬂash chromatography on silica
gel to afford the product (2.46 g, 99%) as colorless oil.
1H-NMR (400 MHz, CDCL3) d: 1.29 (3H, t, J = 7.8 Hz), 4.13 (2H, q,
J = 7.8 Hz), 4.96 (2H, s), 7.27–7.48 (3H, m), 7.61 (1H, s).
ESI-MS: m/z = 206 (M+H)+.
4.3.2. Synthesis of 2-(3-cyanophenoxy)acetic acid
To a solution of ethyl 2-(3-cyanophenoxy)acetate (616 mg,
3 mmol) in THF (12 ml), distilled water (6 ml) and 4 mM lithiumhydroxide (3.75 ml) were added. The mixture was stirred at room
temperature for 1 h. The mixture was diluted with 1 N hydrochlo-
ric acid to reach pH < 1 and extracted with dichloromethane
(20 ml). The organic phase was washed with brine (20 ml), dried
over with magnesium sulfate, and evaporated in vacuo to give
the desired product (531 mg, 99%) as white solid.
1H-NMR (400 MHz, CDCL3) d: 4.08 (2H, s), 7.27–7.48 (3H, m),
7.64(1H, s).
ESI-MS: m/z = 178 (M+H)+.
4.3.3. Synthesis of 2-(3-(aminomethyl)phenoxy)acetic acid
To a solution of 2-(3-cyanophenoxy)acetic acid (100 mg,
0.564 mmol) in methanol (1.2 ml), acetic acid (1.2 ml) and Pd-C
(10 mg) were added. The mixture was stirred at room temperature
under H2 gas for 4 h. The reaction mixture was ﬁltered and the ﬁl-
trate was evaporated in vacuo to give the desired product (138 mg,
99%) as white solid.
1H-NMR (400 MHz, CDCL3) d: 4.36 (2H, s), 4.66 (2H, s), 6.79–
7.01 (3H, m), 7.15 (1H, s).
ESI-MS: m/z = 182 (M+H)+.
4.3.4. Synthesis of 2,2,2-trichloroethyl (5-(furan-2-yl)-1,3,4-
oxadiazol-2-yl)carbamate
To a solution of 5-(furan-2-yl)-1,3,4-oxadiazol-2-amine (3.02 g,
20 mmol) in THF (80 ml), 1,4-dioxane (40 ml), N-ethyl-N-
isopropylpropan-2-amine (3.88 g, 30 mmol), and 2,2,2-
trichloroethyl carbonochloridate (4.45 g, 21 mmol) were added.
The mixture was stirred at room temperature for 20 h. The reaction
mixture was evaporated under reduced pressure. The residue was
puriﬁed by ﬂash chromatography on silica gel to afford the product
(5.11 g, 78%) as white solid.
1H-NMR (400 MHz, CDCL3) d: 4.84 (2H, s), 6.68 (1H, dd, J = 1.5,
7.5 Hz), 7.08 (1H, dd, J = 1.5, 7.5 Hz), 7.86 (1H, dd, J = 1.5, 7.5 Hz),
9.15 (1H, bs).
ESI-MS: m/z = 325, 327 (M + H)+.
4.3.5. Synthesis of 2-(3-((3-(5-(furan-2-yl)-1,3,4-oxadiazol-2-
yl)ureido)methyl)phenoxy)acetic acid (Ligand1)
To a solution of 2,2,2-trichloroethyl (5-(furan-2-yl)-1,3,4-oxadia
zol-2-yl)carbamate (0.098 g, 0.3 mmol) and 2-(3-(aminomethyl)
phenoxy)acetic acid (0.072 g, 0.3 mmol) in acetonitrile (1.5 ml),
N-ethyl-N-isopropylpropan-2-amine (0.081 g, 0.63 mmol) was
added. The mixture was stirred at 333 K for 12 h. The reaction mix-
ture was cooled to room temperature and evaporated under
reduced pressure. The residue was puriﬁed by ﬂash chromatogra-
phy on silica gel to afford the product (0.090 g, 84%) as white solid.
1H-NMR (400 MHz, DMSO-d6) d: 4.38 (2H, d, J = 5.6 Hz), 4.65
(2H, s), 6.78 (2H, tt, J = 5.12, 2.56 Hz), 6.91 (2H, tt, J = 5.6, 8.0 Hz),
7.18 (1H, td, J = 2.2, 1.22 Hz), 7.25 (1H, t, J = 7.93 Hz), 8.01 (2H,
m, J = 1.6 Hz), 11.6 (1H, brs), 13.0 (1H, brs).
ESI-MS: m/z = 359 (M+H)+.
4.4. Expression of Keap1
We have expressed the Kelch domain of human Keap1 (residues
321–609) in Escherichia coli system using a modiﬁed protocol from
the original method described by Li et al. [50]. A hexahistidine tag
comprising 20 residues was added to the N-terminus. The plasmid
encodingKeap1was digestedwithNdeI and BamHI, and the fragment
was inserted into the expression vector pET15b (Novagen) linearized
withNdeI and BamHI. Luria–Bertanimedium containing carbenicillin
was inoculated with a single colony of E. coli BL21(DE3) (Novagen)
carrying recombinant plasmid and grown at 310 K with vigorous
shaking. Plusgrow medium (Nacalai tesque) containing carbenicillin
was inoculated with resulting Luria–Bertani medium and grown at
310 K to reach an optical density of 0.8 at 600 nm. Then, the Keap1
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tion of 0.4 mM at 293 K. The cells were harvested by centrifugation
at 5000g for 10 min and stored at 193 K.
4.5. Puriﬁcation
The cell pellets were treated with BugBuster HT Protein
Extraction Reagent (Novagen). The soluble fraction was applied
onto a His-Trap HP column (GE healthcare) equilibrated with the
binding buffer [500 mM sodium chloride, 20 mM sodium phos-
phate buffer pH 7.4]. The column was washed with 2% Buffer A
[1 M imidazole, 500 mM sodium chloride, 20 mM sodium phos-
phate buffer pH 7.4], and the His-tagged protein was eluted with
30% Buffer A. The eluate was concentrated by ultraﬁltration using
an Amicon Ultra-15 (Millipore, 10,000 cut-off) and applied onto a
HiLoad 16/60 Superdex 200 column (GE healthcare Amersham)
equilibrated with Buffer B [150 mM sodium chloride, 20 mM DTT
(dithiothreitol), 20 mM Tris–HCl pH 8.3]. Peak fractions containing
the protein were pooled, diluted with Buffer C [20 mM DTT, 25 mM
Tris–HCl pH 8.0], and applied onto a HiTrap Q FF column (GE
healthcare) equilibrated with 10% Buffer D [1 M sodium chloride,
20 mM DTT, 25 mM Tris–HCl pH 8.0]. The protein was eluted with
linear gradient of 10–40% Buffer D. The purity of the protein sam-
ple was evaluated by SDS–PAGE, which showed a single band on
the coomassie-stained gel. The puriﬁed protein solution was
desalted and concentrated using Amicon Ultra-15 (Millipore,
10,000 cut-off) to its ﬁnal composition [12 mg ml1 Keap1,
150 mM sodium chloride, 20 mM DTT, 20 mM Tris–HCl pH 8.3]
and stored at 193 K.
4.6. Crystallization, soaking and cryoprotection
Apo-form crystals were obtained using the hanging-drop
vapor-diffusion method at 277 K. The crystallization drop was pre-
pared by mixing equal volumes (1.0 ll) of the protein solution
[12 mg ml1 Keap1, 150 mM sodium chloride, 20 mM DTT,
20 mM Tris–HCl pH 8.3] and the precipitant solution [10%
PEG6000, 10 mM magnesium chloride, 200 mM HEPESNaOH pH
7.0]. Hexagonal rounded crystals grew in 3–7 days to an approxi-
mate size of 60  60  60 lm. To prepare the soaking form of the
Keap1–Ligand1 complex, the apo-form crystals were soaked in a
precipitant solution saturated with Ligand1 at 277 K for 30 min.
The cocrystallization with Ligand1 was performed in the same
way as the apo-form crystallization except for using different pro-
tein solution as a suspension with solid Ligand1 [8 mg ml1 Keap1,
150 mM sodium chloride, 20 mM DTT, 20 mM Tris–HCl pH 8.3,
3.5 mM Ligand1] and different precipitant solution [10%
PEG3350, 0.1 M calcium acetate pH7.5]. Although the actual con-
centration of Ligand1 in solution state in the crystallization drop
was assumed to be less than 1 mM, the saturation level would be
kept during crystallization because of using the suspension state.
Orthorhombic crystals with low diffraction quality grew in seven
days to an approximate size of 10  60  10 lm. To obtain
high-resolution crystals of the cocrystallization form, these crystals
were used for the seeding in which the seed crystals were added to
another crystallization drop at three days after the crystallization
setup. The high-resolution orthorhombic crystals grew in seven
days after the seeding to an approximate size of
10  60  10 lm. All crystals for the X-ray data collection were
frozen using a cryoprotectant solution consisting of 30% (v/v) ethy-
lene glycol in the crystallization precipitant solution.
4.7. X-ray data collection and structure determination
X-ray diffraction data were collected at the beamline BL26B2 of
SPring-8, Japan. The X-ray wavelength used was 1.0 Å with thecrystal-to-detector distance of 200 mm and the oscillation angle
of 1. For both the soaking and the cocrystallization forms, com-
plete diffraction data sets were obtained to 2.1 Å resolution at
100 K. The data were processed and scaled using the HKL2000 pro-
gram package [51]. The crystal structures were solved by the
molecular replacement method using the program MOLREP [52]
from the CCP4 program suite [53], using an available structure of
the human Keap1 Kelch domain (PDB entry 1u6d) [30] as a search
model. Reﬁnement was carried out using the programs REFMAC5
[54] and CNX (Accelrys Inc.) [55]. The structure was visualized
and modiﬁed using the program Coot [56]. Several rounds of man-
ual ﬁtting and reﬁnement were carried out through careful inspec-
tion of 2Fo  Fc and Fo  Fc electron-density maps. The
stereochemical quality of the ﬁnal structures was checked using
the program PROCHECK [57]. The statistics from crystallographic
analysis are given in Table 1. The superposition of models was per-
formed using the program LSQKAB [58] from the CCP4 suite. The
visualization of molecules in ﬁgures was prepared using the pro-
gram Quanta 2000 (Accelrys Inc.) for Figs. 3–5, and the program
Discovery Studio (Accelrys Inc.) for Fig. 7.
4.8. Molecular dynamics calculations
The molecular dynamics (MD) simulation was performed using
the program Discovery Studio v4.0.100.13344 (Accelrys Inc.) using
the CHARMm force ﬁeld [59]. The atomic coordinates of 3vng
and 3vnh are read into Discovery Studio without crystal water
molecules. The protonation state was estimated using the pK pre-
diction function of Discovery Studio; the total charge of molecules
including Ligand1 was set to 5 at pH 7.4. The system in a trun-
cated octahedron cell adopted the periodical boundary condition
with the molecule-boundary distance of 20 Å. The systemwas then
explicitly solvated and neutralized by adding Na+ and Cl ions to
reach an ionic strength of 0.145. Each cell contained: 4334 protein
atoms, 39 ligand atoms, 46 Na+ ions, 41 Cl ions and 46,560 water
atoms for the soaking form (3vnh); 4334 protein atoms, 39 ligand
atoms, 47 Na+ ions, 42 Cl ions and 47,430 water atoms for the
cocrystallization form (3vng). The simulation protocol was com-
posed of six sequential stages: the steepest descent minimization
with the target gradient of 1.0 kcal mol1 Å1; the ﬁrst heating
stage from 0 to 10 K for 0.1 ps with the step duration of 0.1 fs;
the ﬁrst equilibration stage at 10 K for 1 ps with the step duration
of 0.1 fs; the second heating stage from 50 to 300 K for 4 ps with
the step duration of 2 fs; the second equilibration stage at 300 K
for 10 ps with the step duration of 2 fs; the ﬁnal NPT production
stage using the leap-frog integrator at 300 K for 20 ns with the ref-
erence pressure of 1.0 atm and with the step duration of 2 fs. The
SHAKE condition [60] was off in the ﬁrst three stages whereas it
was applied in the later stages. The particle-mesh Ewald method
[61] was selected for the electrostatic calculation throughout the
stages. The coordinates of the trajectory were recorded every
20 ps. The numbers of processors used for the calculation were 8
or 16. Unless otherwise noted, the parameter was set to the default
value in Discovery Studio. The temperature ﬂuctuation during the
production stage was comparable to that estimated from the
degree of freedom of the system. The number of interatomic con-
tacts in the MD structure was calculated using the program
CONTACT in the CCP4 suite [53]. The cluster analysis was per-
formed using Perl scripts based on the method described by
Daura et al. [45] where a series of non-overlapping clusters was
obtained. First, Rmsd from a superposition of relevant atoms was
calculated between all pairs of structures. Then, for each structure,
the number of the other neighbor structures with the Rmsd value
less than a cutoff value was calculated. The cutoff value of Rmsd
was determined by a searching around 70% of the average intratra-
jectory Rmsd.
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